Nature’s pharmacy
An in-depth look at medical cannabis from Professor Trevor Jones
Read More
Search Results for: Professor Trevor Jones
Offering prizes for low-return drugs a ‘flawed concept’, says Prof Jones
PharmaTimes World News online talks to Professor Trevor Jones CBE, one-time Group R&D Director at Wellcome (and at Sigma-Tau) and more recently a Commissioner at the World Health Organisation, about Ebola and research on low-return medicines.
Read MoreSynexus buyout completed, Jones appointed board chairman
Private equity firm Lyceum Capital has now completed its buyout of Synexus Clinical Research, the UK company that pioneered the ‘hub site’ strategy for recruiting patients into late-stage clinical trials. Lyceum has also brought in a pharmaceutical industry veteran, Professor Trevor Jones CBE, to steer Synexus’ international expansion programme.
Read More
Vote of confidence?
Post-election jitters have struck pharma after a surprise result for the UK. With Brexit on the horizon and a minority government in charge, has the industry’s optimism been dashed?
Read More- Cambridge researchers develop robotic nerve devices for neurological conditions
- International phase 3 clinical trial for new melanoma treatment recruits first patients
- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
